Suppr超能文献

今天和明天的卵巢癌:基于 GLOBOCAN 2020 的全球按世界区域和人类发展指数评估。

Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020.

机构信息

Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.

The Royal Marsden NHS Foundation Trust, London, UK.

出版信息

Int J Cancer. 2022 Nov 1;151(9):1535-1541. doi: 10.1002/ijc.34002. Epub 2022 Mar 30.

Abstract

Ovarian cancer remains to have relatively poor prognosis particularly in low-resourced settings. It is therefore important to continually examine the burden of ovarian cancer to identify areas of disparities. Our study aims to provide an overview of the global burden of ovarian cancer using the GLOBOCAN 2020 estimates by country, world region, and Human Development Index (HDI) levels, as well as the predicted future burden by the year 2040 by HDI. Age-standardized incidence and mortality rates for ovarian cancer in 185 countries were calculated by country, world region, and for the four-tier HDI. The number of new cases and deaths were projected for the year 2040 based on demographic projections by HDI category. Approximately 314 000 new ovarian cancer cases and 207 000 deaths occurred in 2020. There were marked geographic variations in incidence rates, with the highest rates observed in European countries with very high HDI and low rates were found in African countries within the lowest HDI group. Comparable mortality rates were observed across the four-tier HDI. Relative to 2020 estimates, our projection for 2040 indicates approximately 96% and 100% increase in new ovarian cancer cases and deaths, respectively, among low HDI countries compared to 19% and 28% in very high HDI countries. Our study highlights the disproportionate current and future burden of ovarian cancer in countries with lower HDI levels, calling for global action to reduce the burden and inequality of ovarian cancer in access to quality cancer care and treatment.

摘要

卵巢癌的预后仍然较差,特别是在资源匮乏的环境中。因此,不断检查卵巢癌的负担,以确定差距领域非常重要。我们的研究旨在利用 GLOBOCAN 2020 按国家、世界区域和人类发展指数 (HDI) 水平估算的结果,以及按 HDI 预测的 2040 年未来负担,概述全球卵巢癌负担。按国家、世界区域和四层次 HDI 计算了 185 个国家的卵巢癌年龄标准化发病率和死亡率。根据 HDI 类别预测的人口预测,预计 2040 年的新发病例和死亡人数。2020 年,约有 314000 例新卵巢癌病例和 207000 例死亡。发病率存在明显的地域差异,发病率最高的是人类发展指数非常高的欧洲国家,而发病率最低的是人类发展指数最低组的非洲国家。在四层次的 HDI 中,死亡率相当。与 2020 年的估计相比,我们对 2040 年的预测显示,与人类发展指数非常高的国家相比,低人类发展指数国家的新卵巢癌病例和死亡人数分别增加了约 96%和 100%,而高人类发展指数国家的病例和死亡人数分别增加了 19%和 28%。我们的研究强调了低 HDI 国家当前和未来卵巢癌负担不成比例的问题,呼吁采取全球行动,以减少全球卵巢癌负担和不平等现象,改善获得优质癌症护理和治疗的机会。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验